Federal Vaccine Mandates: What Both Private and Public Sector Employers Need to Know

With the ushering in of a new administration, companies and their counsel will need to update their compliance measures to reflect the changing enforcement priorities of regulatory agencies, state Attorney Generals, and the DOJ. Hear from industry leaders to help you prepare for the upcoming changes and provide a road map for stress-free compliance.

The discussion will focus on the latest developments with the California and other states’ privacy initiatives as well as the future of data privacy within the U.S. and how in-house counsel can prepare effectively. Specifically, our panelists will explore how to adapt your privacy operations and what is the scope of the application for each regulation.

This panel will present a primer on the U.S. pharmaceutical industry, focusing on the typical capital structures of pharmaceutical/development companies versus in-pipeline companies. The panelists will examine the factors leading to the recent surge in pharmaceutical bankruptcy cases and their outcomes/resolutions, as well as ? 363 sales of pharmaceutical companies’ assets and restructurings. Opiate bankruptcy cases such as Purdue and Mallinckrodt will be highlighted, as will ancillary issues that arise in pharmaceutical bankruptcy cases, such as product recalls, regulatory issues (such as with the FDA) and IP licensing issues.

This panel will discuss various issues and challenges accompanying sales of health care assets, including factors to consider in determining whether or not a sale is the best alternative. Such factors include the role of regulatory authorities, political challenges, reimbursement issues, issues related to urban vs. rural facilities, the evolution of the health care business, and best practices in navigating such challenges.